RS67123B1 - Čvrsti oblici promotera spinogeneze - Google Patents

Čvrsti oblici promotera spinogeneze

Info

Publication number
RS67123B1
RS67123B1 RS20250668A RSP20250668A RS67123B1 RS 67123 B1 RS67123 B1 RS 67123B1 RS 20250668 A RS20250668 A RS 20250668A RS P20250668 A RSP20250668 A RS P20250668A RS 67123 B1 RS67123 B1 RS 67123B1
Authority
RS
Serbia
Prior art keywords
spinogenesis
promoter
solid forms
solid
forms
Prior art date
Application number
RS20250668A
Other languages
English (en)
Inventor
Stella T Sarraf
Elizabeth Büchler Vadas
Original Assignee
Spinogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spinogenix Inc filed Critical Spinogenix Inc
Publication of RS67123B1 publication Critical patent/RS67123B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RS20250668A 2019-01-31 2020-01-30 Čvrsti oblici promotera spinogeneze RS67123B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962799644P 2019-01-31 2019-01-31
EP20747738.1A EP3917521B1 (en) 2019-01-31 2020-01-30 Solid forms of a promoter of spinogenesis
PCT/US2020/015967 WO2020160332A1 (en) 2019-01-31 2020-01-30 Solid forms of a promoter of spinogenesis

Publications (1)

Publication Number Publication Date
RS67123B1 true RS67123B1 (sr) 2025-09-30

Family

ID=71841255

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20250668A RS67123B1 (sr) 2019-01-31 2020-01-30 Čvrsti oblici promotera spinogeneze

Country Status (12)

Country Link
US (1) US12486287B2 (sr)
EP (2) EP3917521B1 (sr)
JP (2) JP7572361B2 (sr)
CN (2) CN119490468A (sr)
AU (2) AU2020214830B2 (sr)
ES (1) ES3032326T3 (sr)
HR (1) HRP20250780T1 (sr)
HU (1) HUE072464T2 (sr)
PL (1) PL3917521T3 (sr)
RS (1) RS67123B1 (sr)
SM (1) SMT202500291T1 (sr)
WO (1) WO2020160332A1 (sr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7168650B2 (ja) 2017-08-02 2022-11-09 スピノジェニックス， インコーポレイテッド ベンゾチアゾールおよび関連化合物
SMT202500291T1 (it) 2019-01-31 2025-09-12 Spinogenix Inc Forme solide di un promotore di spinogenesi
EP4294391A4 (en) * 2021-02-22 2024-12-18 Spinogenix, Inc. METHODS OF TREATING SPINAL CORD INJURY OR DAMAGE
AU2022241760A1 (en) * 2021-03-23 2023-10-05 Spinogenix, Inc. Certain fascin binding compounds for spinogenesis
EP4687886A1 (en) * 2023-04-03 2026-02-11 Spinogenix, Inc. Methods of dosing spinogenic compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US6576654B1 (en) 1998-09-23 2003-06-10 Eli Lilly And Company Method for the treatment of cystic fibrosis
RU2324686C2 (ru) * 2000-08-24 2008-05-20 Юнивесити Оф Питсбэг ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
US20120253047A1 (en) * 2004-03-19 2012-10-04 Dipharma S.P.A. Process for the preparation of (r)-pramipexole
CN101102796A (zh) 2004-11-17 2008-01-09 阿雷斯贸易股份有限公司 苯并噻唑制剂及其用途
WO2007011834A2 (en) 2005-07-15 2007-01-25 The Regents Of The University Of California Compounds and method for the diagnosis and treatment of amyloid associated diseases
TW201018678A (en) * 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
KR101395146B1 (ko) 2011-02-09 2014-05-16 부산대학교 산학협력단 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
ES2877570T3 (es) 2012-08-22 2021-11-17 Univ Cornell Métodos para inhibir fascina
WO2014134287A1 (en) 2013-02-27 2014-09-04 The Regents Of The University Of California Improving cognitive function
CN103554482B (zh) 2013-10-29 2017-01-25 西安近代化学研究所 一种端羟基聚乙二醇对甲苯磺酸酯的合成方法
US9573946B2 (en) 2014-02-20 2017-02-21 Novita Pharmaceuticals, Inc. Compounds and methods for inhibiting fascin
CA3010445A1 (en) 2016-01-05 2017-07-13 The Regents Of The University Of California Benzothiazole amphiphiles
TWI586367B (zh) 2016-03-28 2017-06-11 蔡懷楨 磷酸甘油酯激酶增加神經突生長及／或治療神經性疾病的用途
WO2019005682A1 (en) 2017-06-26 2019-01-03 Spinogenix, Inc. USE OF BENZOTHIAZOLE AMPHIPHILES TO TREAT TRAUMATIC BRAIN INJURY
JP7168650B2 (ja) * 2017-08-02 2022-11-09 スピノジェニックス， インコーポレイテッド ベンゾチアゾールおよび関連化合物
EP3843846A4 (en) 2018-08-27 2022-09-07 Spinogenix, Inc. FASCIN-BINDING COMPOUNDS FOR SPINOGENESIS
SMT202500291T1 (it) 2019-01-31 2025-09-12 Spinogenix Inc Forme solide di un promotore di spinogenesi

Also Published As

Publication number Publication date
WO2020160332A1 (en) 2020-08-06
AU2020214830B2 (en) 2025-10-23
US20220106330A1 (en) 2022-04-07
EP4620527A3 (en) 2025-12-17
CN119490468A (zh) 2025-02-21
JP2022523106A (ja) 2022-04-21
JP2025004201A (ja) 2025-01-14
EP3917521C0 (en) 2025-05-28
EP3917521A1 (en) 2021-12-08
AU2026200464A1 (en) 2026-02-12
CN113727710A (zh) 2021-11-30
CA3128280A1 (en) 2020-08-06
HRP20250780T1 (hr) 2025-09-12
US12486287B2 (en) 2025-12-02
EP3917521B1 (en) 2025-05-28
HUE072464T2 (hu) 2025-11-28
SMT202500291T1 (it) 2025-09-12
PL3917521T3 (pl) 2025-10-20
AU2020214830A1 (en) 2021-09-16
JP7572361B2 (ja) 2024-10-23
ES3032326T3 (en) 2025-07-17
EP4620527A2 (en) 2025-09-24
EP3917521A4 (en) 2022-10-26

Similar Documents

Publication Publication Date Title
ZA202207543B (en) Pyridazinyl-thiazolecarboxamide compound
SMT202500291T1 (it) Forme solide di un promotore di spinogenesi
IL291172A (en) new compounds
GB202103470D0 (en) Promoter
GB202011800D0 (en) Compound
GB201905233D0 (en) A consumable
GB201917867D0 (en) Polymorphs
GB201912404D0 (en) New compounds
IL284564A (en) Polymorphic forms of a modified quinoline-type bridged piperidine compound
GB201903499D0 (en) Minimal promoter
GB2597010B (en) Mooring assembly
CA195589S (en) Part of a trampoline
GB202109231D0 (en) Promoter
GB202304841D0 (en) Promoter
GB202009410D0 (en) Promoter design
GB201905220D0 (en) Forskolin-inducible promoters
GB201905219D0 (en) Hypoxia-enducible promoters
GB2580745B (en) Life extension assembly for structures
GB201918032D0 (en) New polymorphs
GB202000007D0 (en) A searchlight
GB201910664D0 (en) Novel forms of compound
GB202005473D0 (en) Forskolin-inducible promoters
GB2588828B (en) Balustrade
GB201906531D0 (en) Acoustic liner
CA189948S (en) Ring